Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinska AkadfiledCriticalMedizinska Akad
Priority to BG9368291ApriorityCriticalpatent/BG50997A1/en
Publication of BG50997A1publicationCriticalpatent/BG50997A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Saccharide Compounds
(AREA)
Abstract
This agent is used in medicine; for example, for ray therapy in oncological practice. It has reduced toxicity and optimised radio sensitisation effect. Description : adenosin-5'-monophosphate, adenosine-5'-triphosphate, and N-(2-hydroxyethyl)-2-nitro-1H-imidazol-1-acetamide interact in proportions of 1:1 to 1:2, in the presence of water and alcohol-water.
BG9368291A1991-01-221991-01-22Method for the producing of radiosensibilizing substance
BG50997A1
(en)
IMMUNORREAGENT RADIOACTIVE MARKING, COMPOSITION AND FORMATION PROCESS OF DIAGNOSTIC IMAGE, THERAPEUTIC COMPOSITION, TREATMENT PROCESS AND SICK SILIOS AND MATERIAL COMPOSITION